Obseva Logo highresolution.jpg
ObsEva Announces Dismissal of Moratorium Proceedings
December 19, 2022 07:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
Obseva Logo highresolution.jpg
ObsEva Announces Dismissal of Moratorium Proceedings
December 19, 2022 01:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
Obseva Logo highresolution.jpg
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
December 14, 2022 07:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – December 14, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
Obseva Logo highresolution.jpg
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
December 14, 2022 01:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – December 14, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
Obseva Logo highresolution.jpg
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
December 09, 2022 07:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 9, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
Obseva Logo highresolution.jpg
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
December 09, 2022 01:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 9, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
Obseva Logo highresolution.jpg
ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update
December 01, 2022 16:01 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 1, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN) (“ObsEva” or the “Company”), a biopharmaceutical...
Obseva Logo highresolution.jpg
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
November 22, 2022 07:00 ET | ObsEva SA
Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale proceeds are expected to enable ObsEva to...
Obseva Logo highresolution.jpg
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
November 22, 2022 01:00 ET | ObsEva SA
Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale proceeds are expected to enable ObsEva to...
Obseva Logo highresolution.jpg
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings
October 26, 2022 17:00 ET | ObsEva SA
Transition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $16.0 million savings expected from assignment of program contracts, including $3.7...